Clinical trials
Phase 1/2 Stomach Neoplasms trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
68 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 6 |
| 2021 | 6 |
| 2022 | 8 |
| 2023 | 6 |
| 2024 | 6 |
| 2025 | 8 |
| 2026 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 20 |
| Recruiting | 20 |
| Active, not recruiting | 11 |
| Completed | 9 |
| Terminated | 3 |
| Withdrawn | 2 |
| Not yet recruiting | 2 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 4 |
| Ruijin Hospital | 4 |
| Chongqing Precision Biotech Co., Ltd | 3 |
| Beijing Biotech | 2 |
| Chinese Academy of Medical Sciences | 2 |
| Essen Biotech | 2 |
| Hutchison Medipharma Limited | 2 |
| PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2 |
| Shenzhen BinDeBio Ltd. | 2 |
| West China Hospital | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Stomach Neoplasms | 68 |
| Pancreatic Neoplasms | 14 |
| Colorectal Neoplasms | 12 |
| Carcinoma, Non-Small-Cell Lung | 11 |
| Breast Neoplasms | 10 |
| Carcinoma, Hepatocellular | 9 |
| Esophageal Neoplasms | 9 |
| Lung Neoplasms | 9 |
| Ovarian Neoplasms | 9 |
| Biliary Tract Neoplasms | 6 |
Trials
Showing 1 to 25 of 68. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.